Trials / Completed
CompletedNCT00311428
Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months
A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Three Commercially Available Influenza Vaccines in Healthy Subjects Aged 6 to <36 Months.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 270 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 6 Months – 35 Months
- Healthy volunteers
- —
Summary
This phase IV protocol is designed to evaluate the safety, clinical tolerability and immunogenicity of the 2005-2006 formulation of three widely used conventional influenza vaccines in children aged 6 to 35 months
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Influenza |
Timeline
- Start date
- 2005-10-01
- First posted
- 2006-04-06
- Last updated
- 2006-09-14
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT00311428. Inclusion in this directory is not an endorsement.